{{priceData.date}} {{priceData.time}}
{{'2025-06-12T17:06:19Z' | dateFormatFilter}}
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
{{'2025-06-10T12:00:43Z' | dateFormatFilter}}
ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
{{'2025-05-16T11:02:00Z' | dateFormatFilter}}
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.